First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Inclusion Criteria: * Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age greater than or equal to 18 years old at the same time of signing the informed consent. * Histologically or cytologically confirmed Extensive Stage Small Cell Lung Cancer (ES-SCLC) and no prior systemic treatment for ES-SCLC. * Participants with prior treatment for limited-stage SCLC (LS-SCLC) are permitted. * Eastern Cooperative Oncology Group (ECOG) 0 to 1. * Participants with treated asymptomatic brain metastases are eligible provided they meet defined criteria. * Adequate organ function as defined in protocol. Exclusion Criteria: * History of other malignancy within the past 2 years with exceptions. * Major surgery within 28 days of study day 1. * Untreated or symptomatic brain metastases and leptomeningeal disease. * Participants who experienced recurrent grade 2 pneumonitis or severe or life-threatening immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents. * History of immune-related colitis. * History or evidence of interstitial lung disease or active, non-infectious pneumonitis. * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. * Participants with symptoms and/or clinical signs and/or radiogra…